Direkt zum Inhalt
Merck
Alle Fotos(2)

Wichtige Dokumente

SAB4200772

Sigma-Aldrich

Anti-BRAF (V600E) antibody produced in rabbit

enhanced validation

affinity isolated antibody

Synonym(e):

Anti-Proto-oncogene B-Raf, p94, Anti-Serine/threonine-protein kinase B-raf, Anti-v-Raf murine sarcoma viral oncogene homolog B1

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(2)

About This Item

UNSPSC-Code:
12352203
NACRES:
NA.44

Biologische Quelle

rabbit

Qualitätsniveau

200

Antikörperform

affinity isolated antibody

Antikörper-Produkttyp

primary antibodies

Klon

polyclonal

Form

buffered aqueous solution

Mol-Gew.

~95 kDa

Speziesreaktivität

human

Erweiterte Validierung

recombinant expression
Learn more about Antibody Enhanced Validation

Konzentration

~1 mg/mL

Methode(n)

immunoblotting: 2-4 μg/mL using extract of human HEK-293T cells over-expressing BRAF mutant (V600E) protein

UniProt-Hinterlegungsnummer

P15056

Versandbedingung

dry ice

Lagertemp.

−20°C

Posttranslationale Modifikation Target

unmodified

Angaben zum Gen

human ... BRAF(673)

Allgemeine Beschreibung

B-Raf proto-oncogene serine/threonine-protein kinase (BRAF), also known as Serine/threonine-protein kinase B-raf, Proto-oncogene B-Raf, p94, v-Raf murine sarcoma viral oncogene homolog B1, is a member of the RAF family. BRAF is one of the key factors in mitogen-activated protein kinase (MAPK) signaling pathway, which is activated by members of the Ras family upon growth factor-induced stimulation. BRAF controls and regulates numerous essential cellular mechanisms including cell proliferation, differentiation, development, survival, apoptosis and secretion.1-2 In contrast to the majority of oncogenic fusion kinases such as ALK, ROS1, NTRK1 and RET that are receptor tyrosine kinases, BRAF encodes a non-receptor serine/threonine kinase, placing its normal protein localization within the cytoplasm rather than associated with the plasma membrane.3
BRAF is mutated at a high frequency in several cancers, including non-Hodgkin lymphoma, colorectal cancer, malignant melanoma, thyroid carcinoma, nonsmall cell lung carcinoma, and adenocarcinoma of lung.

Spezifität

Anti-BRAF (V600E) recognizes V600E mutated human BRAF protein. The antibody may be used in various immunochemical techniques including Immunoblotting.

Immunogen

Synthetic peptide from the C-terminal region of human BRAF protein, conjugated to KLH

Anwendung

Immunoblotting: a working concentration of 2-4 g/mL is recommended using extract of human HEK-293T cells over-expressing BRAF mutant (V600E) protein.

Physikalische Form

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide

Sie haben nicht das passende Produkt gefunden?  

Probieren Sie unser Produkt-Auswahlhilfe. aus.

Lagerklassenschlüssel

10 - Combustible liquids

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number
077M4858V
51170502

Die passende Version wird nicht angezeigt?

Wenn Sie eine bestimmte Version benötigen, können Sie anhand der Lot- oder Chargennummer nach einem spezifischen Zertifikat suchen.

Suche nach COA

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Nourah Mohammad Obaid et al.
International journal of molecular sciences, 18(3) (2017-03-12)
The development of resistance to previously effective treatments has been a challenge for health care providers and a fear for patients undergoing cancer therapy. This is an unfortunately frequent occurrence for patients undergoing targeted therapy for tumours harboring the activating
Roland Houben et al.
Journal of carcinogenesis, 3, 6-6 (2004-03-30)
Genes of the Raf family encode kinases that are regulated by Ras and mediate cellular responses to growth signals. Recently, it was shown that activating mutations of BRaf are found with high frequency in human melanomas. The Ras family member
Nicolas Stransky et al.
Nature communications, 5, 4846-4846 (2014-09-11)
Human cancer genomes harbour a variety of alterations leading to the deregulation of key pathways in tumour cells. The genomic characterization of tumours has uncovered numerous genes recurrently mutated, deleted or amplified, but gene fusions have not been characterized as
Alexandra Thiel et al.
Frontiers in oncology, 3, 281-281 (2013-12-04)
Different genetic aberrations of BRAF have been reported in various malignancies. BRAF is member of the RAS/RAF/MEK/ERK pathway and constitutive activity of this pathway can lead to increased cellular growth, invasion, and metastasis. The most common activating BRAF mutation in
Sara C Shalin
Laboratory investigation; a journal of technical methods and pathology, 97(2), 158-165 (2016-11-29)
Translocations resulting in a kinase fusion are well reported in many tumor types and indeed can be defining, particularly in the case of hematopoietic malignancies. The recent reports of multiple protein kinase fusions within melanocytic neoplasms, particularly in those with
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.